Teva Reports Positive Austedo Data and Expands Biosimilars Portfolio

Teva Pharmaceuticals reported new clinical data showing effectiveness of Austedo in treating tardive dyskinesia, with improvements observed after three months. The company also launched Ahzantive, a biosimilar version of Eylea, across several European markets to expand its ophthalmology presence.

By Sajjl Nooranne Mon, June 22, 2026 at 4:31 PM GMT+3 2 min read · Yahoo Finance · June 22, 2026, 13:31 UTC

Teva Reports Positive Austedo Data and Expands Biosimilars Portfolio

Tickers: $TEVA

Topics: Ahzantive Austedo biosimilars tardive dyskinesia Teva

Read the full article at Yahoo Finance

More World news

Vecima Networks Reports Q1 Revenue Growth of 37.4% with Non-GAAP EPS of $0.29 Seeking Alpha · November 12, 2026, 14:04 UTC
Elysee Development Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:05 UTC
Skyline Builders Group Holding Signs Term Sheet to Acquire Majority Stake in SuperCritical Materials Seeking Alpha · November 12, 2026, 14:05 UTC
Nvidia Shares Fall Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 14:05 UTC
AeroVironment Secures $405 Million Order for Locust X3 Laser Defense Systems Seeking Alpha · November 12, 2026, 14:06 UTC
Tidewater Renewables Reports Q3 2026 Revenue Growth and Raises Full-Year EBITDA Guidance Seeking Alpha · November 12, 2026, 14:07 UTC
Ambetter from Meridian Reintroduces Marketplace Plans in Metro Detroit for 2027 PR Newswire · November 12, 2026, 14:07 UTC
Disney and Cosm Announce Multiyear Partnership to Bring Star Wars to Immersive Domes CNBC · November 12, 2026, 14:00 UTC
Mercury Insurance Issues Safety Guidelines for Portable Generator Use During Power Outages PR Newswire · November 12, 2026, 14:06 UTC
Paratus Appoints New Senior Leadership to Drive Expansion into Asset-Backed Optimisation PR Newswire · November 12, 2026, 14:03 UTC